Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Itamar Raz

Showing results (221-230 of 254) with videos related to

Pageof 26
Sort By:
American Heart Journal|June 15, 2018
The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 TrialStephen D Wiviott, Itamar Raz, Marc P Bonaca, et al.
Diabetes Care|April 24, 2014
Treatment of recent-onset type 1 diabetic patients with DiaPep277: results of a double-blind, placebo-controlled, randomized phase 3 trialItamar Raz, Anette G Ziegler, Thomas Linn, et al.
European Journal of Heart Failure|December 22, 2023
Natriuretic peptides, body mass index and heart failure risk: Pooled analyses of SAVOR-TIMI 53, DECLARE-TIMI 58 and CAMELLIA-TIMI 61Siddharth M Patel, David A Morrow, Andrea Bellavia, et al.
European Heart Journal|August 24, 2021
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trialKazuma Oyama, Itamar Raz, Avivit Cahn, et al.
Circulation|September 6, 2014
Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trialBenjamin M Scirica, Eugene Braunwald, Itamar Raz, et al.
The New England Journal of Medicine|September 3, 2013
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitusBenjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, et al.
Diabetes Care|January 2, 2015
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 TrialJacob A Udell, Deepak L Bhatt, Eugene Braunwald, et al.
JAMA Cardiology|April 14, 2021
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical TrialThomas A Zelniker, Itamar Raz, Ofri Mosenzon, et al.
Diabetes Care|September 18, 2021
A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With DiabetesDavid D Berg, Stephen D Wiviott, Benjamin M Scirica, et al.
Diabetes, Obesity & Metabolism|August 27, 2020
Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58Avivit Cahn, Stephen D Wiviott, Ofri Mosenzon, et al.
Pageof 26

Showing results (221-230 of 254) with videos related to

Sort By:
Pageof 26
American Heart Journal|June 15, 2018
The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 TrialStephen D Wiviott, Itamar Raz, Marc P Bonaca, et al.
Diabetes Care|April 24, 2014
Treatment of recent-onset type 1 diabetic patients with DiaPep277: results of a double-blind, placebo-controlled, randomized phase 3 trialItamar Raz, Anette G Ziegler, Thomas Linn, et al.
European Journal of Heart Failure|December 22, 2023
Natriuretic peptides, body mass index and heart failure risk: Pooled analyses of SAVOR-TIMI 53, DECLARE-TIMI 58 and CAMELLIA-TIMI 61Siddharth M Patel, David A Morrow, Andrea Bellavia, et al.
European Heart Journal|August 24, 2021
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trialKazuma Oyama, Itamar Raz, Avivit Cahn, et al.
Circulation|September 6, 2014
Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trialBenjamin M Scirica, Eugene Braunwald, Itamar Raz, et al.
The New England Journal of Medicine|September 3, 2013
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitusBenjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, et al.
Diabetes Care|January 2, 2015
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 TrialJacob A Udell, Deepak L Bhatt, Eugene Braunwald, et al.
JAMA Cardiology|April 14, 2021
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical TrialThomas A Zelniker, Itamar Raz, Ofri Mosenzon, et al.
Diabetes Care|September 18, 2021
A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With DiabetesDavid D Berg, Stephen D Wiviott, Benjamin M Scirica, et al.
Diabetes, Obesity & Metabolism|August 27, 2020
Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58Avivit Cahn, Stephen D Wiviott, Ofri Mosenzon, et al.
Pageof 26